Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

被引：486

作者：

Schettini, Francesco ^{[1
,2
,3
]}

Chic, Nuria ^{[2
,3
,4
]}

Braso-Maristany, Fara ^{[2
,4
]}

Pare, Laia ^{[3
]}

Pascual, Tomas ^{[2
,3
,4
,5
]}

Conte, Benedetta ^{[2
,6
]}

Martinez-Saez, Olga ^{[2
,4
]}

Adamo, Barbara ^{[2
,3
,4
]}

Vidal, Maria ^{[2
,3
,4
]}

Barnadas, Esther ^{[2
]}

Fernandez-Martinez, Aranzazu ^{[5
]}

Gonzalez-Farre, Blanca ^{[2
,3
,7
]}

Sanfeliu, Esther ^{[2
,3
,7
]}

Cejalvo, Juan Miguel ^{[8
]}

Perrone, Giuseppe ^{[9
]}

Sabarese, Giovanna ^{[9
]}

Zalfa, Francesca ^{[9
]}

Peg, Vicente ^{[10
,11
]}

Fasani, Roberta ^{[12
]}

Villagrasa, Patricia ^{[3
]}

Gavila, Joaquin ^{[3
,13
]}

Barrios, Carlos H. ^{[14
,15
]}

Lluch, Ana ^{[11
,16
,17
]}

Martin, Miguel ^{[11
,18
]}

Locci, Mariavittoria ^{[19
]}

De Placido, Sabino ^{[1
]}

Prat, Aleix ^{[2
,3
,4
]}

机构：

[1] Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy

[2] August Pi & Sunyer Biomed Res Inst, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain

[3] SOLTI Breast Canc Res Grp, Barcelona, Spain

[4] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[5] Univ N Carolina, Dept Genet, Chapel Hill, NC 27515 USA

[6] Univ Genoa, Osped Policlin San Martino, Dept Med Oncol, Genoa, Italy

[7] Hosp Clin Barcelona, Dept Pathol, Barcelona, Spain

[8] Univ Valencia, Hosp Clin Univ Valencia, INCLIVA Biomed Res Inst, Valencia, Spain

[9] Campus Biomedico Univ, Pathol Dept, Rome, Italy

[10] Vall dHebron Univ Hosp, Barcelona, Spain

[11] Grp Espanol Invest Canc Mama, GEICAM, Madrid, Spain

[12] Inst Valenciano Oncol IVO, Valencia, Spain

[13] Ctr Pesquisa Clin Hosp Sao Lucas PUCRS, Porto Alegre, RS, Brazil

[14] Latin Amer Cooperat Oncol Grp, LACOG, Porto Alegre, RS, Brazil

[15] Latin Amer Cooperat Oncol Grp, LACOG, Porto Alegre, RS, Brazil

[16] Hosp Univ Clin Valencia, Valencia, Spain

[17] Biomed Res Ctr Network Canc CIBERONC, Valencia, Spain

[18] Hosp Gregorio Maranon, Madrid, Spain

[19] Univ Naples Federico II, Dept Neurosci Reprod Sci & Dent, Naples, Italy

来源：

NPJ BREAST CANCER | 2021年 / 7卷 / 01期

关键词：

COMPREHENSIVE MOLECULAR PORTRAITS; AMERICAN SOCIETY; ONCOLOGY/COLLEGE; CHEMOTHERAPY; LETROZOLE;

D O I：

10.1038/s41523-020-00208-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to be elucidated. Here, we collected retrospective clinicopathological and PAM50 data from 3,689 patients with HER2-negative disease and made the following observations. First, the proportion of HER2-low was higher in HR-positive disease (65.4%) than triple-negative BC (TNBC, 36.6%). Second, within HR-positive disease, ERBB2 and luminal-related genes were more expressed in HER2-low than HER2 0. In contrast, no gene was found differentially expressed in TNBC according to HER2 expression. Third, within HER2-low, ERBB2 levels were higher in HR-positive disease than TNBC. Fourth, HER2-low was not associated with overall survival in HR-positive disease and TNBC. Finally, the reproducibility of HER2-low among pathologists was suboptimal. This study emphasizes the large biological heterogeneity of HER2-low BC, and the need to implement reproducible and sensitive assays to measure low HER2 expression.

引用

页数：13

共 46 条

[1] Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial [J].

Adamo, Barbara ;

Bellet, Meritxell ;

Pare, Laia ;

Pascual, Tomas ;

Vidal, Maria ;

Perez Fidalgo, Jose A. ;

Blanch, Salvador ;

Martinez, Noelia ;

Murillo, Laura ;

Gomez-Pardo, Patricia ;

Lopez-Gonzalez, Ana ;

Amillano, Kepa ;

Canes, Jordi ;

Galvan, Patricia ;

Gonzalez-Farre, Blanca ;

Gonzalez, Xavier ;

Villagrasa, Patricia ;

Ciruelos, Eva ;

Prat, Aleix .

BREAST CANCER RESEARCH, 2019, 21 (01)

[2]

[Anonymous], 2016, SOURC DAT GDAC FIR P

[3]

Armitage P, 2001, STAT METHODS MED RES

[4]

Banerji S., 2012, WHOLE EXOME SEQUENCI

[5] Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study [J].

Banerji, Udai ;

van Herpen, Carla M. L. ;

Saura, Cristina ;

Thistiethwaite, Fiona ;

Lord, Simon ;

Moreno, Victor ;

Macpherson, Iain R. ;

Boni, Valentina ;

Rolfo, Christian ;

de Vries, Elisabeth G. E. ;

Rottey, Sylvie ;

Geenen, Jilt ;

Eskens, Ferry ;

Gil-Martin, Marta ;

Mommers, Ellen C. ;

Koper, Norbert P. ;

Aftimos, Philippe .

LANCET ONCOLOGY, 2019, 20 (08) :1124-1135

[6] The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data [J].

Cerami, Ethan ;

Gao, Jianjiong ;

Dogrusoz, Ugur ;

Gross, Benjamin E. ;

Sumer, Selcuk Onur ;

Aksoy, Buelent Arman ;

Jacobsen, Anders ;

Byrne, Caitlin J. ;

Heuer, Michael L. ;

Larsson, Erik ;

Antipin, Yevgeniy ;

Reva, Boris ;

Goldberg, Arthur P. ;

Sander, Chris ;

Schultz, Nikolaus .

CANCER DISCOVERY, 2012, 2 (05) :401-404

[7] Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer [J].

Ciriello, Giovanni ;

Gatza, Michael L. ;

Beck, Andrew H. ;

Wilkerson, Matthew D. ;

Rhie, Suhn K. ;

Pastore, Alessandro ;

Zhang, Hailei ;

McLellan, Michael ;

Yau, Christina ;

Kandoth, Cyriac ;

Bowlby, Reanne ;

Shen, Hui ;

Hayat, Sikander ;

Fieldhouse, Robert ;

Lester, Susan C. ;

Tse, Gary M. K. ;

Factor, Rachel E. ;

Collins, Laura C. ;

Allison, Kimberly H. ;

Chen, Yunn-Yi ;

Jensen, Kristin ;

Johnson, Nicole B. ;

Oesterreich, Steffi ;

Mills, Gordon B. ;

Cherniack, Andrew D. ;

Robertson, Gordon ;

Benz, Christopher ;

Sander, Chris ;

Laird, Peter W. ;

Hoadley, Katherine A. ;

King, Tari A. ;

Perou, Charles M. .

CELL, 2015, 163 (02) :506-519

[8] Results of a Randomized Phase IIb Trial of Nelipepimut-S thorn Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer [J].

Clifton, G. Travis ;

Hale, Diane ;

Vreeland, Timothy J. ;

Hickerson, Annelies T. ;

Litton, Jennifer K. ;

Alatrash, Gheath ;

Murthy, Rashmi K. ;

Qiao, Na ;

Philips, Anne V. ;

Lukas, Jason J. ;

Holmes, Jarrod P. ;

Peoples, George E. ;

Mittendorf, Elizabeth A. .

CLINICAL CANCER RESEARCH, 2020, 26 (11) :2515-2523

[9] Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US [J].

Cronin, Kathleen A. ;

Harlan, Linda C. ;

Dodd, Kevin W. ;

Abrams, Jeffrey S. ;

Ballard-Barbash, Rachel .

CANCER INVESTIGATION, 2010, 28 (09) :963-968

[10]

Eirew P., 2015, WHOLE GENOME TARGETE

← 1 2 3 4 5 →